Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Pediatric Nephrology
Published in: Pediatric Nephrology 3/2014

01-03-2014 | Educational Review

Hypophosphatemic rickets due to perturbations in renal tubular function

Authors: Maria Goretti M. G. Penido, Uri S. Alon

Published in: Pediatric Nephrology | Issue 3/2014

Login to get access

Abstract

The common denominator for all types of rickets is hypophosphatemia, leading to inadequate supply of the mineral to the growing bone. Hypophosphatemia can result from insufficient uptake of the mineral from the gut or its disproportionate losses in the kidney, the latter being caused by either tubular abnormalities per se or the effect on the tubule of circulating factors like fibroblast growth factor-23 and parathyroid hormone (PTH). High serum levels of the latter result in most cases from abnormalities in vitamin D metabolism which lead to decreased calcium absorption in the gut and hypocalcemia, triggering PTH secretion. Rickets is a disorder of the growth plate and hence pediatric by definition. However, it is important to recognize that the effect of hypophosphatemia on other parts of the skeleton results in osteomalacia in both children and adults. This review addresses the etiology, pathophysiologic mechanisms, clinical manifestations and treatment of entities associated with hypophosphatemic rickets due to perturbations in renal tubular function.
Literature
1.
Tiosano D, Hochberg D (2009) Hypophosphatemia: the common denominator of all rickets. J Bone Miner Metab 27:392–401PubMedCrossRef
2.
3.
Dunn PM (1998) Francis Glisson (1597–1677) and the “discovery” of rickets. Arch Dis Child Fetal Neonatal Ed 78:F154–F155PubMedCrossRef
4.
5.
Rajakumar K (2003) Vitamin D, cod-liver oil, sunlight, and rickets: a historical perspective. Pediatrics 112:e132–e135PubMedCrossRef
6.
Sabbagh Y, Carpenter TO, Demay MB (2005) Hypophosphatemia leads to rickets by impairing caspase-mediated apoptosis of hypertrophic chondrocytes. Proc Natl Acad Sci USA 102:9637–9642PubMedCrossRef
7.
Miedlich SU, Zalutskaya A, Zhu ED, Demay MB (2010) Phosphate-induced apoptosis of hypertrophic chondrocytes is associated with a decrease in mitochondrial membrane potential and is dependent upon Erk1/2 phosphorylation. J Biol Chem 285:18270–18275PubMedCrossRef
8.
Kasarkis E, Schuna A (1980) Serum Alkaline phosphatase after treatment of zinc deficiency in humans. Am J Clin Nutr 33:2609–2612
9.
Raimann A, Ertl DA, Helmreich M, Sagmeister S, Egerbacher M, Haeusler G (2013) Fibroblast growth factor 23 and Klotho are present in the growth plate. Connect Tissue Res 54:108–117PubMedCrossRef
10.
Kawai M, Kinoshita S, Kimoto A, Hasegawa Y, Miyagawa K, Yamazaki M, Ohata Y, Ozono K, Michigami T (2013) FGF-23 suppresses chondrocyte proliferation in the presence of soluble α-Klotho both in vitro and in vivo. J Biol Chem 288:2414–2427PubMedCrossRef
11.
12.
Gattineni J, Baum M (2010) Regulation of phosphate transport by fibroblast growth factor 23 (FGF-23): implications for disorders of phosphate metabolism. Pediatr Nephrol 25:591–601PubMedCentralPubMedCrossRef
13.
14.
15.
16.
Srivastava T, Alon US (2002) Stage I vitamin D deficiency rickets mimicking pseudohypoparathyroidism type II. Clin Pediatr 41:263–268CrossRef
17.
Menon PS, Madhavi N, Mukhopadhyaya S, Padhy AK, Bal CS, Sharma LK (1994) Primary hyperparathyroidism in a 14 year old girl presenting with bone deformities. J Paediatr Child Health 30:441–443PubMedCrossRef
18.
19.
de Menezes FH, de Castro LC, Damiani D (2006) Hypophosphatemic rickets and osteomalacia. Arq Bras Endocrinol Metabol 50:802–813CrossRef
20.
Chapman T, Sugar N, Done S, Marasigan J, Wambold N, Feldman K (2010) Fractures in infants and toddlers with rickets. Pediatr Radiol 40:1184–1189PubMedCrossRef
21.
Alizadeh Naderi AS, Reilly RF (2010) Hereditary disorders of renal phosphate wasting. Nat Rev Nephrol 6:657–665PubMedCrossRef
22.
Winters RW, Graham JB, Williams TF, McFalls VW, Burnett CH (1958) A genetic study of familial hypophosphatemia and vitamin D resistant rickets with a review of the literature. Medicine (Baltimore) 37:97–142CrossRef
23.
Pereira CM, Andrade CR, Vargas PA, Coletta RD, Almeida OP, Lopes MA (2004) Dental alterations associated with X-linked hypophosphatemic rickets. J Endodontics 30:241–245CrossRef
24.
Fishman G, Miller-Hansen D, Jacobsen C, Shingal VK, Alon US (2004) Hearing impairment in familial X-linked hypophosphatemic rickets. Eur J Pediatr 163:622–623PubMed
25.
Alon US (2011) Clinical practice: fibroblast growth factor (FGF)23: a new hormone. Eur J Pediatr 170:545–554PubMedCrossRef
26.
Morgan JM, Hawley WL, Chenoweth AI, Retan WJ, Diethelm AG (1974) Renal transplantation in hypophosphatemia with vitamin D-resistant rickets. Arch Intern Med 134:549–552PubMedCrossRef
27.
Meyer RA Jr, Meyer MH, Gray RW (1989) Parabiosis suggests a humoral factor is involved in X-linked hypophosphatemia in mice. J Bone Miner Res 4:493–500PubMedCrossRef
28.
Nesbitt T, Coffman TM, Drezner MK (1992) Cross-transplantation of kidneys in normal and Hyp mice: evidence that the Hyp phenotype is unrelated to an intrinsic renal defect. J Clin Invest 89:1453–1459PubMedCentralPubMedCrossRef
29.
The HYP Consortium (1995) A gene (PEX) with homologies to endopeptidases is mutated in patients with X-linked hypophosphatemic rickets. Nat Genet 11:130–136CrossRef
30.
Ereben R, Dagmar M, Wever K, Jonsson K, Juppner H, Lanske B (2005) Overexpression of human PHEX under the β-actin promoter does not fully rescue the hype mouse phenotype. J Bone Miner Res 20:1149–1160CrossRef
31.
Hy C, Lee BH, Kang JH, Ha IS, Cheong HI, Choi Y (2005) A clinical and molecular genetic study of hypophosphatemic rickets in children. Pediatr Res 58:329–333CrossRef
32.
Yuan B, Feng JQ, Bowman S, Liu Y, Blank RD, Lindberg I, Drezner MK (2013) Hexa-D-arginine treatment increases 7B2•PC2 activity in hyp-mouse osteoblasts and rescues the HYP phenotype. J Bone Mineral Res 28:56–72CrossRef
33.
Igaki JM, Yamada M, Yamazakki Y, Koto S, Izawa M, Ariyasy D, Suzuki E, Hasegawa H, Hasegawa Y (2011) High iFGF-23 level despite hypophosphatemia is one of the clinical indicators to make diagnosis of XLH. Endocr J 58:647–655PubMedCrossRef
34.
Alon US, Levy-Olomucki R, Moore WV, Stubbs J, Liu S, Quarles LD (2008) Calcimimetics as an adjuvant treatment for familial hypophosphatemic rickets. Clin J Am Soc Nephrol 3:658–664PubMedCrossRef
35.
Carpenter TO, Mitnick MA, Ellison A, Smith C, Insogna KL (1994) Noctornal hyperparathyroidism: a frequent feature of X-linked hypophosphatemia. J Clin Endocrinol Metab 78:1378–1383PubMed
36.
Alon US, Lovell HB, Donaldson DL (1992) Nephrocalcinosis, hyperparathyroidism and renal failure in familial hypophosphatemic rickets. Clinical Pediatrics 21:180–183CrossRef
37.
Alon US, Monzavi R, Lilien M, Rasoulpour M, Geffner M, Yadin O (2003) Hypertension in hypophosphatemic rickets—role of secondary hyperparathyroidism. Pediatr Nephrol 18:155–158PubMed
38.
Alon U, Donaldson DL, Hellerstein S, Warady BA, Harris DJ (1992) Metabolic and histologic investigation of the nature of nephrocalcinosis in children with hypophosphatemic rickets and the Hyp mouse. J Pediatr 120:899–905PubMedCrossRef
39.
40.
Geller JL, Khosravi A, Kelly MH, Riminucci M, Adams JS, Collins MT (2007) Clinacalcet in the management of tumor-induced osteomalacia. J Bone Miner Res 22:931–937PubMedCrossRef
41.
Jehan F, Gaucher C, Nguyen TM, Walrant-Debray O, Lahlou N, Sinding C, Déchaux M, Garabédian M (2008) Vitamin D receptor genotype in hypophosphatemic rickets as a predictor of growth and response to treatment. J Clin Endocrinol Metab 93:4672–4682PubMedCrossRef
42.
Morey M, Castro-Feijóo L, Barreiro J, Cabanas P, Pombo M, Gil M, Bernabeu I, Díaz-Grande JM, Rey-Cordo L, Ariceta G, Rica I, Nieto J, Vilalta R, Martorell L, Vila-Cots J, Aleixandre F, Fontalba A, Soriano-Guillén L, García-Sagredo JM, García-Miñaur S, Rodríguez B, Juaristi S, García-Pardos C, Martínez-Peinado A, Millán JM, Medeira A, Moldovan O, Fernandez A, Loidi L (2011) Genetic diagnosis of X-linked dominant hypophosphatemic rickets in a cohort study: tubular reabsorption of phosphate and 1,25(OH)2 D serum levels are associated with PHEX mutation type. BMC Med Genet 12:116–127PubMedCentralPubMedCrossRef
43.
Quinlan C, Guegan K, Offiah A, Neill RO, Hiorns MP, Ellard S, Bockenhauer D, Hoff WV, Waters AM (2012) Growth in PHEX-associated X-linked hypophosphatemic rickets: the importance of early treatment. Pediatr Nephrol 27:581–588PubMedCrossRef
44.
Reusz GS, Miltényi G, Stubnya G, Szabó A, Horváth C, Byrd DJ, Péter F, Tulassay T (1997) X-linked hypophosphatemia: effects of treatment with recombinant human growth hormone. Pediatr Nephrol 11:573–577PubMedCrossRef
45.
Huiming Y, Meng M, Chaomin W, Fan Y (2006) Recombinant growth hormone therapy for X-linked hypophos-phatemia in children (Cochrane Review). In: The Cochrane Library, issue 1. Oxford: Update soft-ware
46.
Wilson DM, Lee PDK, Morris AH, Reiter EO, Gertner JM, Marcus R, Rosenfeld RG (1991) Growth hormone therapy in hypophosphatemic rickets. Am J Dis Child 145:1165–1171PubMed
47.
Alon U, Chan JCM (1985) The effect of hydrochlorotiazide and amiloride in renal hypophsphatemic rickets. Pediatrics 75:754–763PubMed
48.
Auron A, Alon US (2005) Resolution of medullary nephrocalcinosis in children with metabolic bone disorders. Pediatr Nephrol 20:1143–1145PubMedCrossRef
49.
Aono Y, Hasegawa H, Yamazaki Y, Shimada T, Fujita T, Yamashida T, Fukumoto S (2011) Anti-FGF-23 neutralizing antibodies ameliorate muscle weakness and decreased spontaneous movement of Hyp mice. J Bone Miner Res 26:803–810PubMedCrossRef
50.
Wöhrle S, Henninger C, Bonny O, Thuery A, Beluch N, Hynes NE, Guagnano V, Sellers WR, Hofmann F, Kneissel M, Graus Porta D (2013) Pharmacological inhibition of FGFR signaling ameliorates FGF-23-mediated hypophosphatemic rickets. J Bone Miner Res 28(4):899–911PubMedCrossRef
51.
Bianchine JW, Stambler AA, Harrison HE (1971) Familial hypophosphatemic rickets showing autosomal dominant inheritance. Birth Defects Orig Arctic Ser 7:287–295
52.
Gribaa M, Younes M, Bouyacoub Y, Korbaa W, Ben Charfeddine I, Touzi M, Adala L, Mamay O, Bergaoui N, Saad A (2009) An autosomal dominant hypophosphatemic rickets phenotype in a Tunisian family caused by a new FGF-23 missense mutation. J Bone Miner Metab 28:111–115PubMedCrossRef
53.
Econs MJ, McEnery PT (1997) Autosomal dominant hypophosphatemic rickets/osteomalacia: clinical characterization of a novel renal phosphate-wasting disorder. J Clin Endocrinol Metab 82:674–681PubMedCrossRef
54.
Feng JQ, Ward LM, Liu S, Lu Y, Xie Y, Yuan B, Yu X, Rauch F, Davis SI, Zhang S, Rios H, Drezner MK, Quarles LD, Bonewald LF, White KE (2006) Loss of DMP1 causes rickets and osteomalacia and identifies a role for osteocytes in mineral metabolism. Nat Genet 38:310–1315CrossRef
55.
Chapurlat RD, Orcel P (2008) Fibrous dysplasia of bone and McCune–Albright syndrome. Best Pract Res Clin Rheumatol 22:55–69PubMedCrossRef
56.
Haeusler G, Freilinger M, Dominkus M, Egerbacher M, Amann G, Kolb A (2012) Tumor-induced hypophosphatemic rickets in an adolescent boy—clinical presentation, diagnosis, and histological findings in growth plate and muscle tissue. J Clin Endocrinol Metab 130:1818–1821
57.
Gore MO, Welch BJ, Geng W, Kabbani W, Maalouf NM, Zerwekh JE, Moe OW, Sakhaee K (2009) Renal phosphate wasting due to tumor-induced osteomalacia: a frequently delayed diagnosis. Kidney Int 76:342–347PubMedCentralPubMedCrossRef
58.
Chalew SA, Lovchik JC, Brown CM, Sun CC (1996) Hypophophatemia induced in mice by transplantation of a tumor-deprived cell line from a patient with oncogenic rickets. J Pediatr Endocrinol Metab 9:593–597PubMedCrossRef
59.
Xia WB, Jiang Y, Li M, Xing XP, Wang O, Hu YY, Zhang HB, Liu HC, Meng XW, Zhou XY (2010) Levels and dynamic changes of serum fibroblast growth factor 23 in hypophosphatemic rickets/osteomalacia. Chin Med J (Engl) 123:1158–1162
60.
Sethi SK, Hari P, Bagga A (2010) Elevated FGF-23 and parathormone in linear nevus sebaceous syndrome with resistant rickets. Pediatr Nephrol 25:1577–1578PubMedCrossRef
61.
Narazaki R, Ihara K, Namba N, Matsuzaki H, Ozono K, Hara T (2012) Linear nevus sebaceous syndrome with hypophosphatemic rickets with elevated FGF-23. Pediatr Nephrol 27:861–863PubMedCrossRef
62.
Brownstein CA, Adler F, Nelaon-Williams C, Iijima J, Li P, Imura A, Nabeshima Y, Reyes-Mugica M, Carpenter TO, Lifton RP (2008) A translocation causing increased alpha-klotho level results in hypophosphatemic rickets and hyperparathyroidism. Proc Natl Acad Sci USA 105:3455–3460PubMedCrossRef
63.
Imura A, Tsuji Y, Murata M, Maeda R, Kubota K, Iwano A, Obuse C, Togashi K, Tominaga M, Kita N, Tomiyama K, Iijima J, Nabeshima Y, Fujioka M, Asato R, Tanaka S, Kojima K, Ito J, Nozaki K, Hashimoto N, Ito T, Nishio T, Uchiyama T, Fujimori T, Nabeshima Y (2007) alpha-Klotho as a regulator of calcium homeostasis. Science 316:1615–1618PubMedCrossRef
64.
Alexander RT, Woudenberg-Vrenken TE, Buurman J, Dijkman H, van der Eerden BC, van Leeuwen JP, Bindels RJ, Hoenderop JG (2009) Klotho prevents renal calcium loss. J Am Soc Nephrol 20:2371–2379PubMedCrossRef
65.
Lorenz-Depiereux B, Benet-Pages A, Eckstein G, Tenenbaum-Rakover Y, Wagenstaller J, Tiosano D, Gershoni-Baruch R, Albers N, Lichtner P, Schnabel D, Hochberg Z, Strom TM (2006) Hereditary hypophosphatemic rickets with hypercalciuria is caused by mutations in the sodium-phosphate cotransporter gene SLC34A3. Am J Hum Genet 78:193–201PubMedCentralPubMedCrossRef
66.
Tieder M, Modai D, Samuel R, Arie R, Halabe A, Bab I, Gabizon D, Liberman UA (1985) Hereditary hypophosphatemic rickets with hypercalciuria. N Engl J Med 312:611–617PubMedCrossRef
67.
Jaureguiberry G, Carpenter TO, Forman S, Juppner H, Bergwitz C (2008) A novel missense mutation in SLC34A3 that causes hereditary hypophosphatemic rickets with hypercalciuria in humans identifies threonine 137 as an important determinant of sodium-phosphate cotransport in NaPi-IIc. Am J Physiol Renal Physiol 295:F371–F379PubMedCrossRef
68.
Levtchenko EN, Monnens LA, Bokenkamp A, Knoers NV (2007) From gene to disease: Dent’s disease caused by abnormalities in the CLCN5 and OCRL1 genes. Ned Tijdschr Geneeskd 151:2377–2380PubMed
69.
Magen D, Berger L, Coady MJ, Ilivitzki A, Militianu D, Tieder M, Selig S, Lapointe JY, Zelikovic I, Skorecki K (2010) A loss-of-function mutation in NaPi-IIa and renal Fanconi’s syndrome. N Engl J Med 362:1102–1109PubMedCrossRef
Metadata
Title
Hypophosphatemic rickets due to perturbations in renal tubular function
Authors
Maria Goretti M. G. Penido
Uri S. Alon
Publication date
01-03-2014
Publisher
Springer Berlin Heidelberg
Published in
Pediatric Nephrology / Issue 3/2014
Print ISSN: 0931-041X
Electronic ISSN: 1432-198X
DOI
https://doi.org/10.1007/s00467-013-2466-z

Other articles of this Issue 3/2014

Pediatric Nephrology 3/2014 Go to the issue

Clinical Quiz

An unusual cause of severe rickets: Questions

Original Article

Citrate anticoagulation for continuous renal replacement therapy in small children

Letter to the Editors

Risk factors for early relapse during maintenance therapy after a single infusion of rituximab in children with steroid-dependent nephrotic syndrome

Original Article

Growth of children with end-stage renal disease undergoing daily hemodialysis

Letter to the Editors

Corticosteroid therapy can be delayed but not omitted in idiopathic tubulointerstitial nephritis

Educational Review

Renal consequences of parenteral nutrition